Malaria: Hijacker Parasite Blocked From Infiltrating Blood
News Jan 05, 2018 | Original story from the Walter and Eliza Hall Institute
This is a WEHI.TV still of malaria parasite (yellow-green) traveling in the bloodstream. Credit: Dr Drew Berry, Walter and Eliza Hall Institute
A major international collaboration led by Melbourne researchers has discovered that the world's most widespread malaria parasite infects humans by hijacking a protein the body cannot live without. The researchers were then able to successfully develop antibodies that disabled the parasite from carrying out this activity.
The study, led by the Walter and Eliza Hall Institute's Associate Professor Wai-Hong Tham and Dr Jakub Gruszczyk, found that the deadly malaria parasite Plasmodium vivax (P. vivax) causes infection through latching onto the human transferrin receptor protein, which is crucial for iron delivery into the body's young red blood cells.
Published today in Science, the discovery has solved a mystery that researchers have been grappling with for decades.
Associate Professor Tham, who is also a HHMI-Wellcome International Research Scholar, said the collective efforts of teams from Australia, New Zealand, Singapore, Thailand, United Kingdom, United States, Brazil and Germany had brought the world closer to a potential effective vaccine against P.vivax malaria.
"P. vivax currently inflicts a huge burden on global health. It is the most common malaria parasite in countries outside of Africa, with more than 16 million clinical cases recorded each year.
"The parasite can lie dormant in the liver for months on end without causing any symptoms, which makes it very sneaky and difficult to treat," Associate Professor Tham said.
"We now know that P. vivax is hijacking the human transferrin receptor which is essential for transporting iron into the body's young red blood cells.
"Being able to stop P. vivax from latching onto this receptor and infliltrating the blood is a major breakthrough and important step towards malaria elimination," she said.
Dr Gruszczyk said once the teams understood how the parasite was gaining entry into the cells, they were able to design antibodies to block the mode of access.
"Using the Australian Synchrotron in Melbourne, we generated a 3D map of the parasite protein which is the mechanism P. vivax uses to latch onto the human transferrin receptor and enter the young red blood cells.
"This map provided an unprecedented view of the parasite protein's shape, which guided the design of antibodies to block P. vivax from gaining entry into the human cells," Dr Gruszczyk said.
Associate Professor Tham said they were thrilled to see the antibodies successfully block P. vivax invasion using parasites from both Thailand and Brazil. "We are now looking to include collaborative partners in the Pacific, so we can further test the effectiveness of our antibodies," she said.
Study collaborator Dr Jonathan Abraham from Harvard University said the results of the new study aligned with a growing body of evidence that could be used to target multiple infectious diseases.
"Transferrin receptor is also co-opted by five viruses that cause Ebola-like diseases in South America. These diseases are known as New World haemorrhagic fevers.
"Our increasing understanding of how several pathogens are taking advantage of transferrin receptor, means we are getting closer to disrupting infection for a number of deadly diseases," Dr Abraham said.
This article has been republished from materials provided by Walter and Eliza Hall Institute. Note: material may have been edited for length and content. For further information, please contact the cited source.
Towards Personalized Medicine: One Type of Data is Not EnoughNews
To understand the biology of diseased organs researchers use different types of molecular data. One of the biggest computational challenges at the moment is integrating these multiple data types. A new computational method jointly analyses different types of molecular data and disentangles the sources of disease variability to guide personalized treatment.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Simple Sugar Prevents Neurodegeneration in Lysosomal Storage DiseaseNews
New therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB (MPS IIIB)READ MORE